Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avichai Shimoni

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2013
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapiesMichal J Besser, Ronnie Shapira-Frommer, Orit Itzhaki, et al.
Leukemia|February 5, 2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMTJordi Esteve, Sebastian Giebel, Myriam Labopin, et al.
Blood|February 26, 2005
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMTCharles Crawley, Marc Lalancette, Richard Szydlo, et al.
Transplantation and Cellular Therapy|November 7, 2022
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell LymphomaShalev Fried, Roni Shouval, Moneeza Walji, et al.
Leukemia|May 8, 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysisPhilipp Berning, Norbert Schmitz, Maud Ngoya, et al.
Haematologica|December 24, 2025
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysisRonit Marcus, Abraham Avigdor, Uri Greenbaum, et al.
Haematologica|June 20, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphomaOhad Benjamini, Shalev Fried, Roni Shouval, et al.
Transplantation and Cellular Therapy|March 1, 2026
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell LymphomaMarina Gomez-Llobell, Roni Shouval, Samantha Brown, et al.
Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2013
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapiesMichal J Besser, Ronnie Shapira-Frommer, Orit Itzhaki, et al.
Leukemia|February 5, 2021
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMTJordi Esteve, Sebastian Giebel, Myriam Labopin, et al.
Blood|February 26, 2005
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMTCharles Crawley, Marc Lalancette, Richard Szydlo, et al.
Transplantation and Cellular Therapy|November 7, 2022
Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell LymphomaShalev Fried, Roni Shouval, Moneeza Walji, et al.
Leukemia|May 8, 2023
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysisPhilipp Berning, Norbert Schmitz, Maud Ngoya, et al.
Haematologica|December 24, 2025
Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysisRonit Marcus, Abraham Avigdor, Uri Greenbaum, et al.
Haematologica|June 20, 2024
Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo</I> large B-cell lymphoma and transformed low-grade B-cell lymphomaOhad Benjamini, Shalev Fried, Roni Shouval, et al.
Transplantation and Cellular Therapy|March 1, 2026
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell LymphomaMarina Gomez-Llobell, Roni Shouval, Samantha Brown, et al.
Journal of Cellular and Molecular Medicine|October 22, 2025
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic LeukaemiaOfrat Beyar-Katz, Ohad Benjamini, Julio Delgado, et al.
Cancer|December 3, 2020
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a studyGautam Borthakur, Yishai Ofran, Martin S Tallman, et al.
Pageof 17